Excessive food intake, obesity and inflammation process in Zucker fa/fa rat pancreatic islets

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Chentouf, Myriam ^a   Dubois, Gregor ^b   Jahannaut, Céline ^a   Castex, Françoise ^a   Lajoix, Anne Dominique ^a   Gross, René ^a   Peraldi Roux, Sylvie ^a  

^a CNRS   (France)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CASPASE 3; CYCLIN D1; INSULIN; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PROTEIN P35; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMAD4 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CALORIC INTAKE; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENDOCRINE DISEASE; FOOD INTAKE; GENE OVEREXPRESSION; HYPERPHAGIA; INFLAMMATION; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET BETA CELL DYSFUNCTION; PHENOTYPE; PROTEIN CLEAVAGE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ZUCKER RAT; ANIMAL; CELL SURVIVAL; CYTOLOGY; EATING; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; IN VITRO STUDY; METABOLISM; PANCREAS ISLET; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALIA; RATTUS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; EATING; FLUORESCENT ANTIBODY TECHNIQUE; INSULIN-SECRETING CELLS; INTERLEUKIN-1; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS; MALE; OBESITY; RATS; RATS, ZUCKER; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-1 TYPE I; RECEPTORS, INTERLEUKIN-6; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79961045591     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022954     Document Type: Article

References (38)

1. Sjöholm A, Nyström T, (2006) Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 22 (1): 4-10.
2. Donath MY, Shoelson SE, (2011) Type 2 diabetes as an inflammatory disease. Nature Rev 11 98: 107.
3. Lee YH, Pratley RE, (2005) The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 5 (1): 70-75.
4. Donath MY, Størling J, Maedler K, Mandrup-Poulsen T, (2003) Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 81 (8): 455-470.
5. Maedler K, (2008) Beta cells in type 2 diabetes- a crucial contribution to pathogenesis. Diabetes Obes Metab 10 (5): 408-420.
6. Maedler K, Dharmadhikari G, Schumann DM, Størling J, (2009) Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther 9 (9): 1177-88.
7. Mandrup-Poulsen T, (1996) The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39 (9): 1005-1029.
8. Eizirik DL, Mandrup-Poulsen T, (2001) A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44 (12): 2115-2133.
9. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112 (12): 1821-1830.
10. Chen A, Mumick S, Zhang C, Lamb J, Dai H, et al. (2005) Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes Res 13 (8): 1311-1320.
11. Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, et al. (2005) Mechanisms of beta-cell death in type 2 diabetes. Diabetes 54 (Suppl 2): S108-13.
12. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, et al. (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110 (6): 851-860.
13. Böni-Schnetzler M, Thorne J, Parnaud G, Marselli L, Ehses JA, et al. (2008) Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab 93 (10): 4065-4074.
14. Lacy PE, Kostianovsky M, (1967) Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16: 35-39.
15. Nunez G, Benedict MA, Hu Y, Inohara N, (1998) Caspases: the proteases of the apoptotic pathway. Oncogene 17: 3237-3245.
16. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X, (1999) Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15: 269-290.
17. McGillicuddy FC, Chiquoine EH, Hinkle CC, Kim RJ, Shah R, et al. (2009) Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway. J Biol Chem J Biol Chem 284 (46): 31936-31944 Epub Sep 200923.
18. Chandrasekar B, Mummidi S, Perla RP, Bysani S, Dulin NO, et al. (2003) Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. J Biol Chem 373: 547-558.
19. Jia D, Taguchi M, Otsuki M, (2005) Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic rats. Metabolism 54: 619-627.
20. Mine T, Miura K, Okutsu T, Mitsui A, Kitahara Y, (2004) Gene expression profile in the pancreatic islets of Goto-Kakizaki (GK) rats with repeated postprandial hyperglycemia. Diabetes 53 (Suppl. 2): 2475A.
21. Borg LA, Eizirik DL, (1990) Short-term exposure of rat pancreatic islets to human interleukin-1 beta increases cellular uptake of calcium. Immunol Lett 26: 253-258.
22. Spinas GA, Palmer JP, Mandrup-Poulsen T, Andersen H, Nielsen JH, et al. (1988) The bimodal effect of interleukin 1 on rat pancreatic beta-cells-stimulation followed by inhibition-depends upon dose, duration of exposure, and ambient glucose concentration. Acta Endocrinol 119: 307-311.
23. Zawalich WS, Diaz VA, (1986) Interleukin 1 inhibits insulin secretion from isolated perifused rat islets. Diabetes 35: 1119-1123.
24. Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J, (1985) Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy 40: 424-429.
25. Sandler S, Eizirik DL, Svensson C, Strandell E, Welsh M, (1991) Biochemical and molecular actions of interleukin-1 on pancreatic beta-cells. Autoimmunity 10 (3): 241-253.
26. Southern C, Schulster D, Green IC, (1990) Inhibition of insulin secretion by interleukin-1 beta and tumour necrosis factor-alpha via an L-arginine-dependent nitric oxide generating mechanism. FEBS Lett 276: 42-44.
27. Welsh N, Eizirik DL, Bendtzen K, Sandler S, (1991) Interleukin-1 beta-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase. Endocrinology 129: 3167-3173.
28. Eizirik DL, Sandler S, Welsh N, Juntti-Berggren L, Berggren PO, (1995) Interleukin-1 beta-induced stimulation of insulin release in mouse pancreatic islets is related to diacylglycerol production and protein kinase C activation. Mol Cell Endocrinol 111: 159-165.
29. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, et al. (1986) Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232: 1545-1547.
30. Corbett JA, Sweetland MA, Wang JL, Lancaster JR Jr, McDaniel ML, (1993) Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc Natl Acad Sci U S A 90: 1731-1735.
31. Maedler K, Schumann DM, Sauter N, Ellingsgaard H, Bosco D, et al. (2006) Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes 10: 2713-2722.
32. Hotamisligil GS, Spiegelman BM, (1994) Tumor-necrosis factor α: a key component of the obesity-diabetes link. Diabetes 43: 1271-1278.
33. Campbell IL, Cutri A, Wilson A, Harrison LC, (1989) Evidence for IL-6 production by and effects on the pancreatic beta-cell. J Immunol 143 (4): 1188-1191.
34. Kristiansen OP, Mandrup-Poulsen T, (2005) Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54 (Suppl 2): S114-24.
35. Ellingsgaard H, Ehses JA, Hammar EB, Van Lommel L, Quintens R, et al. (2008) Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 105 (35): 13163-13168.
36. Choi SE, Choi KM, Yoon IH, Shin JY, Kim JS, et al. (2004) IL-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transpl Immunol 13 (1): 43-53.
37. Wang XQ, Peng YP, Lu JH, Cao BB, Qiu YH, (2009) Neuroprotection of interleukin-6 against NMDA attack and its signal transduction by JAK and MAPK. Neurosci Lett 450 (2): 122-126 Epub 2008 Nov 27.
38. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, et al. (1998) Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47 (8): 1326-1334.